Back to Results

Orexo AB ADR (ORXOY)

Orexo AB ADR is a U.S.-traded depositary receipt representing common stock in Orexo AB (publ), a specialty pharmaceutical company based in Uppsala, Sweden. Through its operating business, Orexo develops and commercializes pharmaceuticals and digital therapies in the United States, the European Union, the United Kingdom, and other international markets. Its marketed products include Zubsolv for opioid use disorder, Abstral for breakthrough cancer pain, and Edluar for insomnia. The company also has a development pipeline that includes OX124 and OX125 for opioid overdose-related uses, OX640 for anaphylaxis, and OX-MPI for endometriosis. In digital health, Orexo offers deprexis for depression, vorvida for alcohol management, and modia for opioid use disorder. Orexo also collaborates with Abera Bioscience AB on nasal powder vaccines using its AmorphOX technology.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-ORXO.Y
$1.30
-6.3% Downside
Fair
Not available
Not available
Fair
0.0%
October 22, 2026
1.6x
26.5x
44.734 M
17.844 M
2.2%
61.1%
1.7
-153.2%
Valuation • Fair Value

Orexo AB ADR (OTC-ORXO.Y) Fair Value by Valuation Model

Review the available estimates for Orexo AB ADR (OTC-ORXO.Y), including EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.30

Estimated downside of 6.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

EPV Fair Value

$1.02

Earnings power value estimate.

Comps Fair Value

$1.35

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for Orexo AB ADR (OTC-ORXO.Y) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Orexo AB ADR (OTC-ORXO.Y)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

1.712 M

Current operating scale indicator.

Revenue Forecast

98.804 K

Forward revenue estimate.

EBITDA

-32.778 M

Current operating profitability reference.

EBITDA Forecast

-29.279 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Orexo AB ADR (OTC-ORXO.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Orexo AB ADR (OTC-ORXO.Y)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-12.19

No elevated caution signal from this screen.

Altman Z-Score

1.7

Lower score that deserves closer risk review.

FCF / Net Income

-153.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Orexo AB ADR (OTC-ORXO.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Orexo AB ADR (OTC-ORXO.Y)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 22, 2026

Days to Earnings

30

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Orexo AB ADR (OTC-ORXO.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Orexo AB ADR (OTC-ORXO.Y) Stock FAQ

Data-supported answers about Orexo AB ADR (OTC-ORXO.Y), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.30
Estimated downside 6.3%
Valuation Rating
Overvalued
Estimated downside of 6.3%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Orexo AB ADR (OTC-ORXO.Y) is $1.30. This implies an estimated downside of 6.3% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 6.3% versus the current market price.

The current financial health read for Orexo AB ADR (OTC-ORXO.Y) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Orexo AB ADR (OTC-ORXO.Y) is October 22, 2026.

The latest available data indicates no current dividend yield for Orexo AB ADR (OTC-ORXO.Y).

The current market capitalization listed for Orexo AB ADR is 44.734 M.

The current enterprise value listed for Orexo AB ADR is 17.844 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Orexo AB ADR is OTC-ORXO.Y, and the stock is listed on OTC Markets.

Orexo AB ADR (OTC-ORXO.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Orexo AB ADR is 2.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Orexo AB ADR is 61.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B